Amends Agreement for Immunosuppressive Drug Aspreva (ASPV), a Canadian biotech, will underwrite part of the costs that Roche (RHHBY) incurs for its clinical work in China on CellCept as a treatment for lupus nephritis. As a result of the changes, Aspreva will take a $20 million charge in the third quarter. At the same time, Asperva and Roche made several other changes in their CellCept agreement. More details...